NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

TherapeuticsMD Inc (NASDAQ:TXMD) posted its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.10) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The business earned $4.13 million during the quarter, compared to analyst estimates of $4.66 million. TherapeuticsMD had a negative return on equity of 63.67% and a negative net margin of 458.49%. The firm's revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.12) EPS. View TherapeuticsMD's Earnings History.

9 brokers have issued 12-month price targets for TherapeuticsMD's shares. Their forecasts range from $6.00 to $28.00. On average, they expect TherapeuticsMD's stock price to reach $14.50 in the next twelve months. View Analyst Ratings for TherapeuticsMD.

TherapeuticsMD saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 57,501,783 shares, an increase of 0.8% from the March 15th total of 57,941,715 shares. Based on an average daily trading volume, of 1,926,644 shares, the days-to-cover ratio is currently 29.8 days. Approximately 33.1% of the shares of the stock are short sold.

Some companies that are related to TherapeuticsMD include Akorn (AKRX), Puma Biotechnology (PBYI), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Global Blood Therapeutics (GBT), Portola Pharmaceuticals (PTLA), AnaptysBio (ANAB), Medicines (MDCO), Motif (MTFB), Intercept Pharmaceuticals (ICPT), Corcept Therapeutics (CORT), Esperion Therapeutics (ESPR), Spectrum Pharmaceuticals (SPPI), Arena Pharmaceuticals (ARNA), Aimmune Therapeutics (AIMT), Cambrex (CBM), Insmed (INSM) and MyoKardia (MYOK).

News stories about TXMD stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TherapeuticsMD earned a coverage optimism score of 0.20 on Accern's scale. They also gave media headlines about the company an impact score of 45.38 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of TXMD stock can currently be purchased for approximately $5.71.

TherapeuticsMD has a market capitalization of $1.24 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]